文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

主要不良肾脏事件定义中的异质性:范围综述。

Heterogeneity in the definition of major adverse kidney events: a scoping review.

机构信息

Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia.

Department of Emergency and Critical Care Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

出版信息

Intensive Care Med. 2024 Jul;50(7):1049-1063. doi: 10.1007/s00134-024-07480-x. Epub 2024 May 27.


DOI:10.1007/s00134-024-07480-x
PMID:38801518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11245451/
Abstract

Acute kidney injury (AKI) is associated with persistent renal dysfunction, the receipt of dialysis, dialysis dependence, and mortality. Accordingly, the concept of major adverse kidney events (MAKE) has been adopted as an endpoint for assessing the impact of AKI. However, applied criteria or observation periods for operationalizing MAKE appear to vary across studies. To evaluate this heterogeneity for MAKE evaluation, we performed a systematic scoping review of studies that employed MAKE as an AKI endpoint. Four major academic databases were searched, and we identified 122 studies with increasing numbers over time. We found marked heterogeneity in applied criteria and observation periods for MAKE across these studies, with some even lacking a description of criteria. Moreover, 13 different observation periods were employed, with 30 days and 90 days as the most common. Persistent renal dysfunction was evaluated by estimated glomerular filtration rate (34%) or serum creatinine concentration (48%); however, 37 different definitions for this component were employed in terms of parameters, cut-off criteria, and assessment periods. The definition for the dialysis component also showed significant heterogeneity regarding assessment periods and duration of dialysis requirement (chronic vs temporary). Finally, MAKE rates could vary by 7% [interquartile range: 1.7-16.7%] with different observation periods or by 36.4% with different dialysis component definitions. Our findings revealed marked heterogeneity in MAKE definitions, particularly regarding component assessment and observation periods. Dedicated discussion is needed to establish uniform and acceptable standards to operationalize MAKE in terms of selection and applied criteria of components, observation period, and reporting criteria for future trials on AKI and related conditions.

摘要

急性肾损伤 (AKI) 与持续性肾功能障碍、透析治疗、透析依赖和死亡率有关。因此,已经采用主要不良肾脏事件 (MAKE) 的概念作为评估 AKI 影响的终点。然而,用于实施 MAKE 的应用标准或观察期似乎因研究而异。为了评估 MAKE 评估的这种异质性,我们对将 MAKE 用作 AKI 终点的研究进行了系统的范围审查。我们搜索了四个主要的学术数据库,并确定了随时间推移数量不断增加的 122 项研究。我们发现这些研究中 MAKE 的应用标准和观察期存在明显的异质性,有些甚至缺乏标准的描述。此外,使用了 13 个不同的观察期,30 天和 90 天最常见。通过估算肾小球滤过率 (34%) 或血清肌酐浓度 (48%) 评估持续性肾功能障碍;然而,该组成部分采用了 37 种不同的定义,涉及参数、截止标准和评估期。透析组件的定义在评估期和透析需求持续时间(慢性与临时)方面也存在显著的异质性。最终,使用不同的观察期或不同的透析组件定义,MAKE 发生率可能相差 7%[四分位距:1.7-16.7%];使用不同的观察期或不同的透析组件定义,MAKE 发生率可能相差 36.4%。我们的研究结果表明,MAKE 定义存在明显的异质性,特别是在组件评估和观察期方面。需要进行专门的讨论,以根据组件的选择和应用标准、观察期以及 AKI 和相关病症的未来试验的报告标准,为 MAKE 的实施建立统一和可接受的标准。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/fcff2f834a74/134_2024_7480_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/bcf0baaa2f3e/134_2024_7480_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/41aa22f638d9/134_2024_7480_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/6667c7fc0917/134_2024_7480_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/f536d1f5fc7e/134_2024_7480_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/fcff2f834a74/134_2024_7480_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/bcf0baaa2f3e/134_2024_7480_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/41aa22f638d9/134_2024_7480_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/6667c7fc0917/134_2024_7480_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/f536d1f5fc7e/134_2024_7480_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede1/11245451/fcff2f834a74/134_2024_7480_Fig5_HTML.jpg

相似文献

[1]
Heterogeneity in the definition of major adverse kidney events: a scoping review.

Intensive Care Med. 2024-7

[2]
Dialysis requirement, long-term major adverse cardiovascular events (MACE) and all-cause mortality in hospital acquired acute kidney injury (AKI): a propensity-matched cohort study.

J Nephrol. 2016-12

[3]
Dialysis Requirement and Long-Term Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease and Superimposed Acute Kidney Injury.

Nephron. 2017

[4]
Parameters used to discontinue dialysis in acute kidney injury recovery: a survey of United States nephrologists.

Nephron. 2015

[5]
Evaluation of five different renal recovery definitions for estimation of long-term outcomes of cardiac surgery associated acute kidney injury.

BMC Nephrol. 2019-11-21

[6]
Renal Outcomes of Dialysis-Dependent Acute Kidney Injury in Noncritically Ill Patients: A Retrospective Study.

Blood Purif. 2022

[7]
The impact of continuous renal replacement therapy on renal outcomes in dialysis-requiring acute kidney injury may be related to the baseline kidney function.

BMC Nephrol. 2017-5-3

[8]
Survival after acute kidney injury requiring dialysis: long-term follow up.

Hemodial Int. 2014-10

[9]
Continued monitoring of acute kidney injury survivors might not be necessary in those regaining an estimated glomerular filtration rate >60 mL/min at 1 year.

Nephrol Dial Transplant. 2017-1-1

[10]
Impact of Acute Kidney Injury in Patients Hospitalized With Pneumonia.

Crit Care Med. 2017-4

引用本文的文献

[1]
Epidemiology and long-term outcomes of critically ill patients with severe AKI in India and Southeast Asia.

Intensive Care Med. 2025-7-14

[2]
Postoperative 20% Albumin Infusion and Acute Kidney Injury in High-Risk Cardiac Surgery Patients: The ALBICS AKI Randomized Clinical Trial.

JAMA Surg. 2025-6-11

[3]
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS).

Trials. 2025-5-30

[4]
Early Driving Pressure Is Associated with Major Adverse Kidney Events at 30 Days in ARDS Patients with SARS-CoV-2.

J Clin Med. 2025-4-17

[5]
Impact of kidney volume on incidence of in-hospital kidney-related adverse outcomes in patients with acute heart failure.

BMC Cardiovasc Disord. 2025-1-28

[6]
Copper-instigated modulatory cell mortality mechanisms and progress in kidney diseases.

Ren Fail. 2025-12

[7]
Fluid balance neutralization secured by hemodynamic monitoring versus protocolized standard of care in patients with acute circulatory failure requiring continuous renal replacement therapy: results of the GO NEUTRAL randomized controlled trial.

Intensive Care Med. 2024-12

[8]
Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE?

Intensive Care Med. 2024-10

本文引用的文献

[1]
Tackling sepsis-associated AKI: are there any chances of REVIVAL with new approaches?

Intensive Care Med. 2024-1

[2]
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).

Intensive Care Med. 2024-1

[3]
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.

JAMA. 2023-10-24

[4]
Kinetic Estimated Glomerular Filtration Rate in Predicting Paediatric Acute Kidney Disease.

J Clin Med. 2023-9-30

[5]
Clinical outcome prediction using observational supervision with electronic health records and audit logs.

J Biomed Inform. 2023-11

[6]
Different Roles of Functional and Structural Renal Markers Measured at Discontinuation of Renal Replacement Therapy for Acute Kidney Injury.

Blood Purif. 2023

[7]
Impact of cardiac surgery associated acute kidney injury on 1-year major adverse kidney events.

Front Nephrol. 2023-4-24

[8]
Designing acute kidney injury clinical trials.

Nat Rev Nephrol. 2024-2

[9]
The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events.

Kidney Int. 2023-12

[10]
The Role of Erythropoietin Levels in Predicting Long-Term Outcomes following Severe Acute Kidney Injury.

Blood Purif. 2023

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索